Effect of solid lipid nanoparticles formulation compositions on their size, zeta potential and potential for in vitro pHIS-HIV-hugag transfection

Pharmaceutical Research

Volumn 24, Issue 6, 2007, Pages 1098-1107

  Asasutjarit, Rathapon ^a   Lorenzen, Sven Iver ^a   Sirivichayakul, Sunee ^a   Ruxrungtham, Kiat ^a   Ruktanonchai, Uracha ^b   Ritthidej, Garnpimol C ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b NATIONAL SCIENCE AND TECHNOLOGY DEVELOPMENT AGENCY   (Thailand)

Author keywords

Face centered central composite design; HIV plasmid DNA vaccine delivery; Size; Solid lipid nanoparticles; Zeta potential

Indexed keywords

4 HYDROXYBENZOIC ACID ESTER; CETYLPALMITATE; CHOLESTEROL; DIMETHYLDIOCTADECYLAMMONIUM BROMIDE; DNA VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PLASMID DNA; POLYSORBATE 80; PROPYLENE GLYCOL; SOLID LIPID NANOPARTICLE; SORBITAN TRIOLEATE; SURFACTANT; UNCLASSIFIED DRUG;

ARTICLE; BIOASSAY; CELL SURVIVAL; CHEMICAL COMPOSITION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXICITY; DRUG FORMULATION; GEL MOBILITY SHIFT ASSAY; GENE TARGETING; HELA CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; PH MEASUREMENT; PRESSURE; PRIORITY JOURNAL; REGRESSION ANALYSIS; STATISTICAL SIGNIFICANCE; WESTERN BLOTTING; ZETA POTENTIAL;

CHEMISTRY, PHARMACEUTICAL; CHOLESTEROL; HELA CELLS; HIV; HUMANS; LIPIDS; NANOPARTICLES; PARTICLE SIZE; SURFACE-ACTIVE AGENTS; TRANSFECTION; VACCINES, DNA;

EID: 34249042347     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-007-9234-3     Document Type: Article

References (23)

1. M. J. Alonso. Nanomedicines for overcoming biological barriers. Biomed. Pharmacother. 58:168-172 (2004).
2. C. Olbrich, U. Bakowsky, C. Lehr, R. H. Müller, and C. Kneuer. Cationic solid-lipid nanoparticles can efficiently bind and transfect plasmid DNA. J. Control Release 77:345-355 (2001).
3. K. Tabatt, C. Kneuer, M. Sameti, C. Olbrich, R. H. Müller, C. Lehr, and U. Bakowsky. Transfection with different colloidal systems: comparison of solid lipid nanoparticles and liposomes. J. Control Release 97:321-332 (2004).
4. K. Tabatt, M. Sameti, C. Olbrich, R. H. Müller, and C. Lehr. Effect of cationic lipid and matrix lipid composition on solid lipid nanoparticles-mediated gene transfer. Eur. J. Pharm. Biopharm. 57:155-162 (2004).
5. P. Calvo, M. J. Alonso, J. L. Vila-Jato, and J. R. Robinson. Improved ocular bioavailability of indomethacin by novel ocular drug carriers. J. Pharm. Pharmacol. 48:1147-1152 (1996).
6. J. Vandervoort and A. Ludwig. Biocompatible stabilizers in the preparation of PLGA nanoparticles: a factorial design study. Int. J. Pharm. 238:77-92 (2002).
7. S. Sierra, B. Kupfer, and R. Kaiser. Basics of the virology of HIV-1 and its replication. J. Clin. Virol. 34:233-244 (2005).
8. C. P. Locher, D. Putnam, R. Langer, S. A. Witt, B. B. Ashlock, and J. A. Levy. Enhancement of a human immunodeficiency virus env DNA vaccine using a novel polycationic nanoparticle formulation. Immunol. Lett. 90:67-70 (2003).
9. W. Mehnert and K. Mäder. Solid lipid nanoparticles production, characterization and applications. Adv. Drug Deliv. Rev. 47:165-196 (2001).
10. M. Chacón, L. Berges, J. Molpeceres, M. R. Aberturas, and M. Guzman. Optimized preparation of poly D,L (lactic-glycolic) microspheres and nanoparticles for oral administration. Int. J. Pharm. 141:81-91 (1996).
11. M. Davoren, S. N. Shúilleabháin, M. G. J. Hartl, D. Sheehan, N. M. O'Brien, J. O'Halloran, F. N. A. M. V. Pelt, and C. Mothersill. Assessing the potential of fish cell lines as tools for the cytotoxicity testing of estuarine sediment aqueous elutriates. Toxicol. In Vitro 19:421-431 (2005).
12. M. A. Schubert and C. C. Müller-Goymann. Characterisation of surface-modified solid lipid nanoparticles (SLN): influence of lecithin and nonionic emulsifier. Eur. J. Pharm. Biopharm. 61:77-86 (2005).
13. T. P. Goloub and R. J. Pugh. The role of the surfactant head group in the emulsification process: binary (nonionic-ionic) surfactant mixtures. J. Colloid Interface Sci. 291:256-262 (2005).
14. S. K. Jain, M. K. Chourasia, R. Masuriha, V. Soni, A. Jain, N. K. Jain, and Y. Gupta. Solid lipid nanoparticles bearing flurbiprofen for transdermal delivery. Drug Deliv. 12:207-215 (2005).
15. E. F. de Souza and O. Teschke. Liposome stability verification by atomic force microscopy. Rev. Adv. Mater. Sci. 5:34-40 (2003).
16. Y. Gu and D. Li. The ζ-potential of silicone oil droplets dispersed in aqueous solutions. J. Colloid Interface Sci. 206:346-349 (1998).
17. P. Ahlin, J. Kristl, and J. Smid-Korbar. Optimization of procedure parameters and physical stability of solid lipid nanoparticles in dispersions. Acta Pharm. 48:259-267 (1998).
18. S. Pang, H. Park, Y. Jang, W. Kim, and J. Kim. Effects of charge density and particle size of poly(styrene/(dimethylamino)ethyl emthacrylate) nanoparticle for gene delivery in 293 cells. Colloids Surf., B Biointerfaces 26:213-222 (2002).
19. A. Roland and S. M. Sullivan. Pharmaceutical Gene Delivery Systems, Marcel Dekker, USA, 2003.
20. M. A. Egan, S. Megati, V. Roopand, D. Garcia-Hand, A. Luckay, S. Chong, M. Rosati, S. Sackitey, D. B. Weiner, B. K. Felber, G. N. Pavlagis, Z. R. Israel, J. H. Eldridge, and M. K. Sidhu. Rational design of plasmid DNA vaccine capable of eliciting cell-mediated immune responses to multiple HIV antigen in mice. Vaccine 24:4510-4523 (2006).
21. Z. Cui and R. J. Mumper. Topical immunization using nanoengineered genetic vaccines. J. Control Release 81:173-184 (2002).
22. C. M. Wiethoff, J. G. Smith, G. S. Koe, and C. R. Middaugh. The potential role of proteoglycans in cationic lipid-mediated gene delivery: studies of the interaction of cationic lipid-DNA complexes with model glycosaminoglycans. J. Biol. Chem. 276:32806-32813 (2001).
23. C. Hung, T. Hwang, C. Chang, and J. Fang. Physicochemical characterization and gene transfection efficiency of lipid emulsions with various co-emulsifiers. Int. J. Pharm. 289:197-208 (2005).